HomeAGIO • NASDAQ
add
Agios Pharmaceuticals Inc
Previous close
$45.76
Day range
$44.80 - $46.95
Year range
$19.80 - $50.35
Market cap
2.65B USD
Avg Volume
350.85K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
In the news
Financials
Income Statement
Revenue
Net income
(USD) | Jun 2024info | Y/Y change |
---|---|---|
Revenue | 8.62M | 28.35% |
Operating expense | 35.54M | 16.86% |
Net income | -96.12M | -14.69% |
Net profit margin | -1.12K | 10.64% |
Earnings per share | -1.69 | -11.92% |
EBITDA | -104.22M | -13.42% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
(USD) | Jun 2024info | Y/Y change |
---|---|---|
Cash and short-term investments | 569.89M | -18.88% |
Total assets | 773.06M | -28.76% |
Total liabilities | 112.55M | -6.92% |
Total equity | 660.51M | — |
Shares outstanding | 56.89M | — |
Price to book | 3.94 | — |
Return on assets | -32.60% | — |
Return on capital | -34.41% | — |
Cash Flow
Net change in cash
(USD) | Jun 2024info | Y/Y change |
---|---|---|
Net income | -96.12M | -14.69% |
Cash from operations | -72.59M | -8.75% |
Cash from investing | 37.24M | -20.97% |
Cash from financing | 1.10M | 363.71% |
Net change in cash | -34.25M | -76.65% |
Free cash flow | -39.24M | -4.53% |
About
Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. The company was founded in 2008 by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013. Wikipedia
Founded
2008
Website
Employees
385